Related Experiment Videos
Molecular screening. Prospects for a new approach
1Department of Otolaryngology-Head and Neck Surgery, The Johns Hopkins University School of Medicine, Baltimore, Md.
Abstract:
Tumors arise through a series of genetic steps that involve alterations of various cellular genes. The recent revolution in molecular genetic techniques has allowed direct identification of genetic changes within tumors. Because these changes are intimately involved in tumor progression, they are specific markers for cancer. A novel assay based on the polymerase chain reaction allows detection of a rare cancer cell containing a specific point mutation among an excess background of normal cells. This technique has allowed identification of p53 gene mutations in pathologic tissue samples from primary head and neck cancer. A small population of cancer cells has been detected in a variety of histologically negative clinical specimens, including saliva, surgical margins, lymph nodes, and chyle. The precise detection of these rare cancer cells in various clinical samples has significant implications for otolaryngology-head and neck surgery. This approach holds promise for screening of head and neck cancer and may call for the reassessment of current histopathologic staging through utilization of new molecular genetic techniques.
Insights
Molecular genetic techniques can detect rare cancer cells with p53 gene mutations in head and neck cancer patients. This breakthrough aids in early cancer screening and may refine current staging methods.
Area of Science:
- Oncology
- Molecular Genetics
- Head and Neck Surgery
Background:
- Tumors develop through genetic alterations, with specific mutations serving as cancer markers.
- Advancements in molecular genetics enable the direct identification of these genetic changes within tumors.
- Identifying rare cancer cells is crucial for accurate diagnosis and staging.
Purpose of the Study:
- To develop and validate a novel assay for detecting rare cancer cells in head and neck cancer.
- To identify p53 gene mutations in pathologic tissue samples from primary head and neck cancer.
- To assess the implications of detecting rare cancer cells in various clinical specimens for otolaryngology-head and neck surgery.
Main Methods:
- Utilized a novel polymerase chain reaction (PCR)-based assay.
- Focused on detecting specific point mutations, such as in the p53 gene.
- Applied the assay to various histologically negative clinical specimens.
Main Results:
- Successfully detected a small population of cancer cells with p53 gene mutations.
- Identified these rare cancer cells in diverse specimens: saliva, surgical margins, lymph nodes, and chyle.
- Demonstrated the assay's ability to find cancer cells amidst a large background of normal cells.
Conclusions:
- The PCR-based assay precisely detects rare cancer cells in clinical samples, offering significant implications for head and neck cancer management.
- This molecular genetic technique shows promise for early head and neck cancer screening.
- The findings may necessitate a re-evaluation of current histopathologic staging methods in head and neck oncology.